Corcept Therapeutics Inc. is a leading pharmaceutical company that is making significant strides in developing innovative treatments for severe metabolic and psychiatric disorders through its pioneering approach to cortisol modulation.

Corcept Therapeutics Inc. saw a surge in its share price after a Phase 3 clinical trial showed promising results for its drug relacorilant in treating platinum-resistant ovarian cancer.

Corcept Therapeutics’ shares surged after a Phase 3 clinical trial showed promising results for its treatment relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer.